Pertuzumab

Pertuzumab
Identifier
External IDs	CAS number : 380610-27-5
Drug information
ATC code	L01 XC13
DrugBank	DB06366
Drug class	Cytostatic , monoclonal antibody

Pertuzumab (also known as 2C4, Omnitarg, trade name Perjeta , manufacturer Genentech / Roche ) is a monoclonal antibody that is used together with trastuzumab and docetaxel in the treatment of HER2- positive breast cancer .

history

Perjeta was developed by Genentech . Approval for the treatment of HER2-positive metastatic breast cancer was granted by the American health authority FDA in June 2012. In 2013, approval in Europe was granted by the European Medicines Agency EMA.

Effective range

The HER family of transmembrane receptor tyrosine kinases and HER2 in particular have been identified as important targets in the fight against breast cancer. The signal transmission through HER plays an essential role in tumor growth as well as in cell differentiation . The recombinant humanized monoclonal antibody pertuzumab binds specifically to the extracellular dimerization domain (subdomain II) of the growth factor receptor protein HER2. The heterodimerization with other receptors (e.g. HER3 and HER4) is also inhibited. This is to prevent the tumor from growing . In addition, pertuzumab is also a mediator for antibody-dependent cell-mediated cytotoxicity ( ADCC, antibody dependent cellular cytotoxicity ).

administration

At the start of therapy, 840 mg pertuzumab is administered together with 8 mg / kg trastuzumab and 75 mg / m ² docetaxel . After three weeks, 420 mg pertuzumab is administered together with 6 mg / kg trastuzumab and 75 or 100 mg / m ² docetaxel.

Side effects

In the clinical studies, neutropenia , insomnia, loss of appetite, diarrhea and vomiting were found as side effects.

Clinical studies

Administration of pertuzumab together with trastuzumab and docetaxel demonstrated significantly increased progression-free survival in the multinational phase III clinical study CLEOPATRA. In other currently ongoing clinical studies MARIANNE (advanced breast cancer), NEOSPHERE (breast cancer in the initial stage) and TRYPHAENA (HER2-positive breast cancer in stage II / III), pertuzumab is being evaluated in patients.

See also

Nomenclature of monoclonal antibodies , convention for naming monoclonal antibodies

Web links

• Video clip about how pertuzumab on the video platform YouTube (English)
• Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for: Pertuzumab

Individual evidence

1. ↑ ^{a b} Highlights of prescribing information. Genentech, accessed June 25, 2014 . 
2. ↑ Data From Omnitarg Clinical Program Presented at the American Society of Clinical Oncology Meeting. Genentech, archived from the original on July 13, 2014 ; accessed on June 28, 2014 . 
3. ↑ FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer. Genentech, accessed June 9, 2012 . 
4. ↑ Roche receives EU approval for PERJETA, a new personalized therapy for the aggressive form of breast cancer. Roche, archived from the original on October 3, 2013 ; Retrieved June 26, 2014 . 
5. ↑ ^{a b} Pertuzumab - Treatment / Therapy for Breast Cancer. drugdevelopment-technology.com, accessed June 26, 2014 . 
6. ↑ ^{a b c d} Summary of Product Characteristics. EMA, accessed June 25, 2014 . 
7. ↑ JS de Bono, J. Bellmunt, G. Attard, JP Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, L. Cockey, M. Mason, J. Graham: Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. In: Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Volume 25, number 3, January 2007, pp. 257-262, doi : 10.1200 / JCO.2006.07.0888 . PMID 17235043 .
8. ↑ pertuzumab. Drugs.com, accessed June 26, 2014 . 
9. ↑ J. Baselga, J. Cortés, SB Kim, SA Im, R. Hegg, YH Im, L. Roman, JL Pedrini, T. Pienkowski, A. Knott, E. Clark, MC Benyunes, G. Ross, SM Swain : Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. In: The New England Journal of Medicine . Volume 366, Number 2, January 2012, pp. 109-119, doi : 10.1056 / NEJMoa1113216 , PMID 22149875 .
10. ^ Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer . In: Drugs 2012 Feb 12; 72 (3): 353-360.

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !